Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $8 | $6 | $0 |
| G&A Expenses | $4 | $4 | $4 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $12 | $10 | $20 |
| Operating Income | -$13 | -$12 | -$10 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $0 | $1 |
| Pre-Tax Income | -$12 | -$11 | -$10 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$11 | -$10 | -$18 |
| % Margin | – | – | – | – |
| EPS | -0.64 | -0.61 | -2.52 | -3.64 |
| % Growth | -4.9% | 75.8% | 30.8% | – |
| EPS Diluted | -0.64 | -0.61 | -2.52 | -3.64 |
| Weighted Avg Shares Out | 19 | 19 | 4 | 5 |
| Weighted Avg Shares Out Dil | 19 | 19 | 4 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$11 | -$9 | -$18 |
| % Margin | – | – | – | – |